RxDoctor Payments Data

Laura Dagani

Family · Findlay, OHNPI 1225478316

Payments from drug & device makers

$3,077in general payments, 2019–2025

Across 29 payments — averaging $106.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$2K
  • Dexcom, Inc.$578
  • Johnson & Johnson$162
  • AstraZeneca$132
  • Insulet Corporation$111
  • Boehringer Ingelheim$103
  • plus $168 from 4 others

What the payments were for

  • Travel & lodging$1,26541%
  • Food & beverage$1,81259%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,077 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$53,154
Medicare patients
186
Services billed
823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide251$283,328
JardianceEmpagliflozin215$212,520
MounjaroTirzepatide182$205,402
TrulicityDulaglutide131$132,298
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog86$125,648
RybelsusSemaglutide50$55,701
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog44$44,166
FarxigaDapagliflozin Propanediol37$39,535
Soliqua 100-33Insulin Glargine/Lixisenatide34$38,033
Tresiba Flextouch U-200Insulin Degludec21$29,504
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog64$28,620
Tresiba Flextouch U-100Insulin Degludec28$27,720
Fiasp FlextouchInsulin Aspart (Niacinamide)41$25,995
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/736$24,835
JanuviaSitagliptin Phosphate21$21,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$103$212,520215 claims
AstraZenecaFarxiga$132$39,53537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Findlay

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →